In our study, we initially assessed the genomic alterations and clinical outcomes among patients diagnosed with adenocarcinoma that underwent transformation to SCLC following treatment with first/second-generation and third-generation EGFR-TKIs. This evidence concerns the gene EGFR and adenocarcinoma.